Observational studyArchives of dermatological research2021
Sentinel lymph node biopsy for high-thickness cutaneous squamous cell carcinoma.
Observational study in Archives of dermatological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Tumor Thickness and Histological Grade as Determinants of Sentinel Lymph Node Metastasis in Cutaneous Squamous Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Cutaneous Squamous Cell Carcinoma Risk Factors: Are Current Criteria Still Valid? A Retrospective, Monocenter Analysis.Life (Basel, Switzerland) · 2025Article
- Surgical management of head and neck squamous cell carcinoma metastatic to the parotid gland.Frontiers in oncology · 2025Review
- Sentinel Lymph Node Biopsy: Is There a Role in Non-Melanoma Skin Cancer? A Systematic Review.Cancers · 2024Review
- Prospective Randomized Study on the Use of Sentinel Node Biopsy for High-risk Cutaneous Squamous Cell Carcinomas of the Head and Neck.Plastic and reconstructive surgery. Global open · 2024Article
- Molecular targeted therapies for cutaneous squamous cell carcinoma: recent developments and clinical implications.EXCLI journal · 2024Review
- Update of advanced cutaneous squamous cell carcinoma.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Review
- Long non-coding RNA PICSAR serves as a non-invasive biomarker for the diagnosis and prognosis of cutaneous squamous cell carcinoma.Clinical and experimental medicine · 2021Article
- Assessment of Histological Features in Squamous Cell Carcinoma Involving Head and Neck Skin and Mucosa.Journal of clinical medicine · 2021Article
- Current Surgical Therapy of Locally Advanced cSCC: From Patient Selection to Microsurgical Tissue Transplant. Review.Frontiers in oncology · 2021Review
- Parotidectomy and neck dissection in locally advanced and relapsed cutaneous squamous cell carcinoma of the head and neck region.Brazilian journal of otorhinolaryngologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Squamous cell carcinomas are among the most common skin tumors and show a risk of metastasis depending on various factors such as tumor thickness, localization, histological subtype and immune status of the patient. Sentinel lymph node biopsy (SLNB) SLNB represents a possibility for assessing the locoregional lymph node status. In this study, the role of the SLNB in lymph node status and survival was analyzed. Retrospectively, 720 patients with high-risk squamous cell carcinoma (tumor thickness > 5 mm) were examined. 150 patients agreed to SLNB, 570 patients did not undergo histologic confirmation of lymph node status and were included directly in follow-up. In 101 patients, a sentinel lymph node was successfully marked and extirpated, followed by regular follow-up examinations.A total of 11.11% of the patients showed lymph node metastasis in the course of their treatment, with no difference in the proportion of patients in the SLNB group (11.9%) and the observation group (11.4%) (p = 0.873). The proportion of distant metastasis also did not differ between the groups (p = 0.898). In 3.96% of the patients in the SLNB group, a metastasis was found in the sentinel lymph node. Tumor-specific death was observed in 7.14% of the patients in the SLNB group and 4.74% in the observation group (p = 0.269). Although SLNB is a principally suitable method for determining lymph node status, the available data do not provide any benefit regarding further metastasis or tumor-specific survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.